CLINICAL TRIALS PROFILE FOR ETELCALCETIDE
✉ Email this page to a colleague
All Clinical Trials for ETELCALCETIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01134549 ↗ | Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers | Completed | Nucleus Network Ltd | Phase 1 | 2010-06-09 | The purpose of this study is to characterize the safety and tolerability of etelcalcetide in healthy young males. |
| NCT01134549 ↗ | Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers | Completed | KAI Pharmaceuticals | Phase 1 | 2010-06-09 | The purpose of this study is to characterize the safety and tolerability of etelcalcetide in healthy young males. |
| NCT01134562 ↗ | Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | Completed | KAI Pharmaceuticals | Phase 1 | 2010-09-07 | The purpose of this study is to characterize the safety and tolerability of single rising doses of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism. |
| NCT01254565 ↗ | Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism | Completed | KAI Pharmaceuticals | Phase 2 | 2011-02-20 | The purpose of this study is to characterize the safety and tolerability and efficacy of multiple ascending doses of etelcalcetide in hemodialysis patients for the treatment of secondary hyperparathyroidism (HPT). |
| NCT01414114 ↗ | Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder | Completed | KAI Pharmaceuticals | Phase 2 | 2011-12-05 | The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD). |
| NCT01576146 ↗ | Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism | Terminated | KAI Pharmaceuticals | Phase 2 | 2012-03-01 | The purpose of this study is to evaluate the long term safety and efficacy of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis who had completed 12 weeks of treatment with etelcalcetide in parent study 20120331 (KAI-4169-005; NCT01414114). |
| NCT01785849 ↗ | Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis | Completed | Amgen | Phase 3 | 2013-03-12 | This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ETELCALCETIDE
Condition Name
| Condition Name for ETELCALCETIDE | |
| Intervention | Trials |
| Secondary Hyperparathyroidism | 8 |
| Hyperparathyroidism, Secondary | 7 |
| Chronic Kidney Disease | 3 |
| Chronic Kidney Disease, Secondary Hyperparathyroidism | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for ETELCALCETIDE
Trials by Country
Clinical Trial Progress for ETELCALCETIDE
Clinical Trial Phase
Clinical Trial Sponsors for ETELCALCETIDE
Sponsor Name
